Enterosys welcomes its new CEO

CEO Jean-Christophe Malrieu

With its unique combination of scientific expertise, R&D skills and state-of-the-art technologies, Enterosys is set to become a leading preclinical contract research organization (CRO) in the market.

Enterosys has a technological lead in the investigation of the digestive sphere. The objective of the company is to become the reference player in the field of the gut, the gut-brain axis and the gut-organ axis.

With such a line of investigation, Enterosys aims to become a key research partner in the field on neurodegenerative, metabolic and intestinal diseases.

Jean-Christophe Malrieu is an entrepreneur with a Master’s degree in Business Management from the University of Paris Dauphine and a Bachelor’s degree in Economics. Before joining SME companies as CEO, he had a long international experience in multinational companies such as Unilever (18 years) and Shiseido (4 years). 

Jean-Christophe has extensive experience in innovation and development, marketing and sales, finance, export, the food and beauty industry, and the healthcare sector for 12 years.  In 2010, he became president and CEO of Phythea, a French nutraceutical leader specializing in joint health and women’s health. In early 2017, he co-founded A-Mansia Biotech SA in Belgium, a spin-off from Wageningen University and UC Leuven aiming to fight obesity and type 2 diabetes with Akkermansia muciniphila, a key bacterium species of the human gut microbiota discovered in 2006 by the company’s founders. In 2018,  Jean-Christophe raised €25 million to fund the development of A-Mansia, including €18 million in a Series A round. In December 2021, he decided to join ENTEROSYS as CEO.




Enterosys welcomes its new assistant engineer

Manon Carratala Lasserre joined the Enterosys team in November 2022 and is in charge of service delivery. She obtained a Master’s degree in Immunology and infectious diseases at the Paul Sabatier University in Toulouse. During her internships, she first worked on...

Enterosys participates in Biofit 2022 in Strasbourg

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing...

Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in a hybrid format. This hybrid event will be held both in-person and online. Enterosys will be present with a validated, complete and...

Enterosys welcomes its new business developer

This month, Pauline Caseilles joined the Enterosys team as a Scientific Business Developer. Her mission: to publicize Enterosys' service offerings. Pauline obtained a Master’s degree in Health Biology and a Specialized Mastere in Marketing and Sales also in the field...

Antioxidant and anti-inflammatory properties of maternal milk

The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks Preterm infants are highly susceptible to oxidative stress due...